Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer

被引：0
|
作者：
Y. F. Yu
Y. Wang
T. P. Fu
K. Chen
J. Q. Liu
H. R. Yao
机构：
[1] Sun Yat-sen Memorial Hospital,Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center
[2] Sun Yat-sen University,Department of Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
[3] Sun Yat-sen University Cancer Center,Department of Oncology
[4] Sun Yat-sen Memorial Hospital,undefined
[5] Sun Yat-sen University,undefined
来源：
Breast Cancer Research and Treatment | 2018年 / 168卷
关键词：
Metastatic breast cancer; HER2-positive; Trastuzumab; Single-agent chemotherapy; Doublet-agent chemotherapy; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：337 / 348
页数：11
相关论文
共 50 条
  • [21] Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer
    Stefanou, Dimitra
    Kokkali, Stefania
    Tripodaki, Elli-Sophia
    Drizou, Maria
    Magou, Elpida
    Zylis, Dimosthenis
    Prevezanou, Maria
    Kapiris, Matthaios
    Nasi, Despoina
    Ntokou, Anna
    Dede, Mary
    Ardavanis, Alexandros
    ANTICANCER RESEARCH, 2018, 38 (11) : 6565 - 6569
  • [22] Weekly paclitaxel and trastuzumab as first-line chemotherapy in patients with her-2 positive metastatic breast cancer
    Kim, Jin-Soo
    Han, Hye-Suk
    Im, Seock-Ah
    Oh, Do-Youn
    Han, Won-Shik
    Lee, Se-Hoon
    Kim, Dong-Wan
    Kim, Tae-You
    Noh, Dong-Young
    Bang, Yung-Jue
    ANNALS OF ONCOLOGY, 2006, 17 : 85 - 85
  • [23] HER2-positive metastatic Breast Cancer Trastuzumab Emtansine: First Choice for the Second Line
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (11) : 744 - 744
  • [24] Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer
    Onder Tonyali
    Mustafa Benekli
    Veli Berk
    Ugur Coskun
    Metin Ozkan
    Ramazan Yildiz
    Emel Ucgul
    Alper Sevinc
    Dogan Uncu
    Umut Demirci
    Suleyman Buyukberber
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 981 - 986
  • [25] Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer
    Tonyali, Onder
    Benekli, Mustafa
    Berk, Veli
    Coskun, Ugur
    Ozkan, Metin
    Yildiz, Ramazan
    Ucgul, Emel
    Sevinc, Alper
    Uncu, Dogan
    Demirci, Umut
    Buyukberber, Suleyman
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (06) : 981 - 986
  • [26] Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China
    Wang, Hao
    Wang, Ye
    Gong, Ruixue
    Geng, Yuyu
    Li, Li
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (11) : 11382 - 11393
  • [27] Evaluation of first-line trastuzumab in combination with epirubicin/cyclophosphamide for patients with HER2-positive metastatic breast cancer.
    Unich, M.
    Tjulandin, S.
    Jonat, W.
    Meerpohl, H.
    Lichinitser, M.
    Manikhas, G. M.
    Janicke, F.
    Muscholl, M.
    Pausehinger, M.
    Thomssen, C.
    Leide, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S185 - S186
  • [28] Comparative efficacy and acceptability of first-line single-agent chemotherapy in metastatic breast cancer.
    Wang, Ying
    Yu, Yunfang
    Ou, Qiyun
    Gao, Quanlong
    Fu, Tuping
    Lin, Dagui
    Yao, Herui
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Trastuzumab, leuprorelin, letrozole, and palbociclib as first-line therapy in HER2-positive and hormone receptor-positive metastatic breast cancer: A case report
    Sun, Maoben
    Cai, Liangzhen
    Chen, Min
    MEDICINE, 2023, 102 (24) : E33975
  • [30] Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)
    Hua, Xin
    Bi, Xi-Wen
    Zhao, Jian-Li
    Shi, Yan-Xia
    Lin, Ying
    Wu, Zhi-Yong
    Zhang, Yuan-Qi
    Zhang, Le-Hong
    Zhang, An-Qing
    Huang, Heng
    Liu, Xin-Mei
    Xu, Fei
    Guo, Ying
    Xia, Wen
    Hong, Ruo-Xi
    Jiang, Kui-Kui
    Xue, Cong
    An, Xin
    Zhong, Yong-Yi
    Wang, Shu-Sen
    Huang, Jia-Jia
    Yuan, Zhong-Yu
    CLINICAL CANCER RESEARCH, 2022, 28 (04) : 637 - 645
12345